2021
DOI: 10.1038/s41594-020-00547-5
|View full text |Cite
|
Sign up to set email alerts
|

Cold sensitivity of the SARS-CoV-2 spike ectodomain

Abstract: The SARS-CoV-2 spike (S) protein, a primary target for COVID-19 vaccine development, presents its receptor binding domain in two conformations, the receptor-accessible 'up' or receptor-inaccessible 'down' states. Here we report that the commonly used stabilized S ectodomain construct '2P' is sensitive to cold temperatures, and this cold sensitivity is abrogated in a 'down' state-stabilized ectodomain. Our findings will impact structural, functional and vaccine studies that use the SARS-CoV-2 S ectodomain.The s… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

8
52
0
1

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 68 publications
(61 citation statements)
references
References 29 publications
8
52
0
1
Order By: Relevance
“…Consistent with previous reports, the monomeric RBD proved quite stable, yielding little change in appearance by SDS-PAGE (Figure S4A), mACE2-Fc and CR3022 binding (Figure S4B), or the ratio of UV/ vis absorption at 320/280 nm, a measure of particulate scattering (Figure S4C). As reported recently (Edwards et al, 2020;Hsieh et al, 2020), the S-2P trimer was unstable at 2 C-8 C, exhibiting clear signs of unfolding by nsEM even at early time points (Figure S3D; Data S2). Instead, S-2P maintained its structure considerably better at 22 C-27 C until the latest time point (28 days), when unfolding was apparent by nsEM and absorbance measurements indicated some aggregation (Figure S4C).…”
Section: Llsupporting
confidence: 80%
See 1 more Smart Citation
“…Consistent with previous reports, the monomeric RBD proved quite stable, yielding little change in appearance by SDS-PAGE (Figure S4A), mACE2-Fc and CR3022 binding (Figure S4B), or the ratio of UV/ vis absorption at 320/280 nm, a measure of particulate scattering (Figure S4C). As reported recently (Edwards et al, 2020;Hsieh et al, 2020), the S-2P trimer was unstable at 2 C-8 C, exhibiting clear signs of unfolding by nsEM even at early time points (Figure S3D; Data S2). Instead, S-2P maintained its structure considerably better at 22 C-27 C until the latest time point (28 days), when unfolding was apparent by nsEM and absorbance measurements indicated some aggregation (Figure S4C).…”
Section: Llsupporting
confidence: 80%
“…Accordingly, the diverse polyclonal Ab responses elicited by the RBD-12GS-I53-50 nanoparticle, targeting multiple distinct epitopes, might explain the magnitude of neutralization observed and should minimize the risk of selection or emergence of escape mutations (Davis et al, 2018;Lee et al, 2019). Finally, the high production yield of RBD-I53-50A components and the robust stability of the antigen-bearing RBD nanoparticles suggests that these will likely be more amenable to large-scale manufacturing than the SARS-CoV-2 S-2P trimer, which expresses poorly and is unstable (Edwards et al, 2020;Hsieh et al, 2020;McCallum et al, 2020).…”
Section: Discussionmentioning
confidence: 99%
“…Cold sensitivity of a spike protein construct is reduced when the protein is engineered to bias towards the closed/down trimer [28]. It is also significantly reduced when the pH is reduced from 7.4 to 6.0, although the molecular origin of this pH effect, and thus whether the D398 – R355 charge pair is involved, is unknown.…”
Section: Resultsmentioning
confidence: 99%
“…Prefusion stabilization through the insertion of two proline mutations was shown to be successful in preventing postfusion transition in the SARS-CoV and MERS-CoV Spike proteins (22), and a similar SARS-CoV-2 Spike design serves as the antigen for the recent COVID-19 vaccines (which have shown up to 95% efficacy in clinical trials) (38,39). However, due to the limited stability and conformational heterogeneity of the SARS-CoV-2 Spike trimer observed here and elsewhere (34), further improvements are needed to expand use for other applications (such as a reagent for eliciting neutralizing antibodies) (3,4,29,(40)(41)(42).…”
Section: Discussionmentioning
confidence: 96%